Currently showing only Legislation & Regulation Resources
Page 3 of 5

A critical juncture for synthetic biology

Publication date: 12/06/2018

The development of new technologies and their applications often have to navigate regulatory limitations and public attitudes, expectations or resistance – the trajectories of genetically modified crops in the Europe or the success of in vitro fertilization after initial resistance demonstrate how public attitudes and regulation can determine if a technology succeeds or fails.

Academic scientists and companies working on new technologies increasingly must consider these factors and mitigate real and perceived risks of the technology so as to avoid overreaching regulation and public resistance that could threaten innovation. In this context, social science takes an important role by gauging public attitudes about if and how the emergence of new technologies stokes fears and raises hopes.

This article illustrates how the natural sciences and social sciences interacted in the emerging fields of synthetic biology and nanotechnology, specifically the timing and rise of social science research and commentary on the potential impact and risks of these emerging technologies.

Resource type: Web page URL

Risk in synthetic biology – views from the lab

Publication date: 01/06/2018

The concepts of risk and responsibility are often linked to discussions of emerging scientific fields, but studies into how these concepts are connected to research practices have been narrowly focused on risks for humans and the environment.

To broaden these concepts, “Responsible Research and Innovation” (RRI), a democratic governance framework, aims to enable societal discussions beyond traditional risk assessment and mitigation. Proponents of RRI argue that these discussions should not be confined to the direct risks of the research itself, but also include wider issues, such as “the purposes and motivations of research” [1]. Yet, it is not only RRI protagonists who want to broaden this conversation.

We found that scientists also ponder non‐technical risks, such as the impact of institutional demands on career, health and social relationships, or economic pressures from the incentive system in which much of research in biology is now embedded. These findings challenge the present formulation of RRI as a science governance framework and lead us to argue that “responsible” research and innovation systems can only succeed if these broader concerns are taken as seriously as the risk of laboratory accident or inadvertent release.

Resource type: Adobe Acrobat (.pdf)

Who’s talking about non-human Genome Editing? Mapping public discussion in the UK

Publication date: 31/05/2018

This report reviews public discussion about Genome Editing in non-human organisms. Its primary goal is to provide a preliminary baseline regarding the kinds of public discussion about, and interactions with, a development in biotechnology with societal significance.

Previous research and experience governing emerging technologies has shown that they need to be developed in ways that are ethical, safe and accountable, that deliver meaningful public value and that foster public trust in democratic institutions. Past experience in Britain suggests public deliberation and discourse has a vital role to play in developing effective governance arrangements and the nation has developed significant institutional expertise in developing such arrangements.

To date, attention has focused largely on the use of Genome Editing in humans. For instance, in 2015 an international summit produced a consensus statement on human Genome Editing. This was followed by a consensus study by the US National Academies of Sciences, Engineering, and Medicine into the ethics and governance of human Genome Editing, published in 2017. However, Genome Editing techniques span virtually all domains of bioscience and biotechnology that rely on altering genetic sequences. In today’s landscape, this means their envisaged uses in both scientific research, as tools, and in developing new technologies or commercially-valuable processes are widespread. It is therefore vital that non-human applications are considered.

In the UK, the Nuffield Council on Bioethics recently concluded an initial study on the ethics of Genome Editing and is undertaking follow up studies on human Genome Editing and Genome Editing in livestock. The Wellcome Trust is currently funding public engagement on Genome Editing as applied to human health and medicine through the Genome Editing Public Engagement Synergy with the National Coordinating Centre for Public Engagement. This review complements the above work by providing baseline information about public discussion of, and public engagement with, Genome Editing in non-human contexts.

Resource type: Adobe Acrobat (.pdf)

A global observatory for gene editing

Publication date: 21/03/2018

In August 2017, scientists reported that they had used the gene-editing tool CRISPR–Cas9 to correct a mutation in viable human embryos. The work is just one of countless applications of the technique, with which scientists hope to alter plants, animals and humans.

The value of most applications of the technology has barely been exposed to public review. Unless these editorial aspirations are more inclusively debated, well-intentioned research could move humanity closer to a future it has not assented to and might not want.

Over the past three years, leading scientists have called for global deliberation on the possible effects of gene editing on the human future. In our view, the discussions that have taken place fall far short of the expansive, cosmopolitan conversation that is needed.

Free enquiry, the lifeblood of science, does not mean untrammelled freedom to do anything. Society’s unwritten contract with science guarantees scientific autonomy in exchange for a research enterprise that is in the service of, and calibrated to, society’s diverse conceptions of the good. As the dark histories of eugenics and abusive research on human subjects remind us, it is at our peril that we leave the human future to be adjudicated in biotechnology’s own “ecclesiastical courts”.

It is time to invite in voices and concerns that are currently inaudible to those in centres of biological innovation, and to draw on the full richness of humanity’s moral imagination. An international, interdisciplinary observatory would be an important step in this direction.

Resource type: article: Web Page

Rethink public engagement for gene editing

Publication date: 12/03/2018

Over the past three years, thousands of articles have been published about editing genes and genomes. Apart from a public dialogue run by the Royal Society at the end of last year, there’s been little attempt to engage the public on the implications of the technology in a way that could alter the decisions of scientists and policymakers. Indeed, concern about the lack of effective public engagement has motivated several workshops, including one by the intergovernmental Organisation for Economic Co-operation and Development (OECD).

If the history of public engagement surrounding other recent scientific innovations is a guide, efforts to explain the science behind gene editing will intensify, such as through news stories, at science festivals, in public lectures and in museums. And there will be a rash of small, disconnected workshops involving members of the public that are designed to inform specific policy decisions.

If this is all that happens, scientists and policymakers will be ill prepared for the public debate that will almost certainly erupt as applications proliferate.

  • Linked page includes option for .pdf download.
Resource type: article: Web Page

Why are NGOs sceptical of genome editing?

Publication date: 02/11/2017

In 2016, 107 Nobel Laureates signed an open letter calling on Greenpeace to desist from campaigning against agricultural biotechnology and for governments to reject and resist such campaigning, arguing that “[o]pposition based on emotion and dogma contradicted by data must be stopped”

The letter marked the latest chapter in a long‐running, heated and apparently intractable debate around agricultural biotechnology. Yet, while the arguments by Greenpeace and other non‐governmental organisations (NGOs) against agricultural biotechnology are frequently dismissed as based on emotion and dogma, their opposition is often grounded on more general scepticisms concerning the framing of the problem and its solutions, and the motivations of actors to employ biotechnology in agriculture.

Genome editing is an important case of agricultural biotechnology. In Europe, however, the European Commission has been delaying a decision on the regulation of genome editing and new plant breeding techniques (NPBT) for use in agriculture.

In the meantime, numerous groups are attempting to influence the debate, including biotechnology companies, scientists and NGOs. Scientists and their representations have been particularly prominent in these debates in contrast to a more muted position from commercial interests as companies have adopted a “wait‐and‐see” strategy with regard to the pending regulatory decision on genome editing.

As with earlier debates on genetically modified (GM) crops, NGOs have become the subject of intense criticism from leading scientists who support genome editing in agriculture. The subsequent debates have aroused passions on all sides, but rarely led to greater mutual understanding.

In this paper, we use the case of genome editing to argue that the Nobel Laureate letter may have mischaracterised opposition to agricultural biotechnology as rooted in emotion and dogma.

Rather, our results suggest that this opposition is grounded in three specific types of scepticism concerning the problem framing of food security; the focus on intensive agriculture and technological solutions to the problem of food security; and the motivations for adopting agricultural biotechnology. Below, we describe our methods for analysing NGO scepticism, before providing more detail on each of three types of scepticism.

Resource type: Adobe Acrobat (.pdf)

New genetic engineering techniques: precaution, risk, and the need to develop prior societal technology assessment

Publication date: 18/08/2017

Business has been arguing that governments should override the precautionary principle in favor of an “innovation principle.” The new genetic engineering techniques (sometimes called “new breeding techniques”)1 provide the perfect cover for this argument. Proponents assure us that these new techniques are essential to address the crises we face and will provide economic benefit, as long as we set aside the precautionary approach that they claim increasingly hampers technological progress. We are in the midst of powerful high-risk technological developments with potentially severe and irreversible health, environmental, and societal implications. It is vital to develop processes for examining new technologies while they are still being developed. We argue that precaution needs to guide technology development in this area. Indeed, it should precede the technology development. An adequate technology assessment and decision-making process requires concerted effort, courage, and restraint, and it must include the option to decide against developing or deploying some technologies altogether.

Resource type: Adobe Acrobat (.pdf)

Addressing socio-economic and ethical considerations in biotechnology governance: the potential of a new politics of care

Publication date: 01/06/2017

There is a growing demand to incorporate social, economic and ethical considerations into biotechnology governance. However, there is currently little guidance available for understanding what this means or how it should be done.

A framework of care-based ethics and politics can capture many of the concerns maintaining a persistent socio-political conflict over biotechnologies and provide a novel way to incorporate such considerations into regulatory assessments. A care-based approach to ethics and politics has six key defining features.

These include: 1) a relational worldview, 2) an emphasis on the importance of context, 3) a recognition of the significance of dependence, 4) an analysis of power, including a particular concern for those most vulnerable, 5) a granting of weight to the significance of affect, and 6) an acknowledgment of an important role for narrative. This policy brief provides an overview of these defining features, illustrates how they can appear in a real world example and provides a list of guiding questions for assessing these features and advancing a politics of care in the governance of biotechnology

Resource type: Adobe Acrobat (.pdf)

Should organic agriculture maintain its opposition to GM? New techniques writing the same old story

Publication date: 28/10/2016

Biotechnology is diversifying rapidly through the development and application of new approaches to genome editing and ongoing research into synthetic biology.

Proponents of biotechnology are enthusiastic about these new developments and have recently begun calling for environmental movements to abandon their campaigns against Genetically Modified Organisms (GMOs) and for organic agriculture to reconsider its exclusion of Genetic Modification (GM).

In this article, we begin by describing the diversity of practices that cluster under both the terms GM and organic and show that although there is a clash of different cultures of agriculture at stake, there is also a spectrum of practices existing between these two poles.

Having established the terms of the debate, we then go on to analyse whether the organic movement should reconsider its position on GM in light of new plant breeding techniques (NPBTs), using the criteria highlighted as important by the International Federation of Organic Agriculture Movements (IFOAM) in their 2016 draft revised position on GMOs.

Through this analysis, we suggest that given the in-context-trajectory of biotechnology development, the continued narrow framing of agricultural problems and the ongoing exclusion of important socio-economic, political and cultural dimensions, the organic movement is justified in maintaining its opposition to GM in the face of NPBTs.

Link goes to full text and .pdf options.

Resource type: Web page URL

Why Frankenstein is a great science policy guide for the guture

Publication date: 27/10/2016

Mary Shelley’s 200-year-old fable explores the tension between scientific creativity and social responsibility.

It is a nuanced exploration of scientific ethics and the dynamic between scientific creativity and social responsibility. The novel isn’t a straightforward warning to stop innovating; it is a cautionary tale. The dangers aren’t so much about what we do, but how we go about doing it.

Shelley’s narrative urges us to be good caretakers of the new things we bring into the world, whether they’re ideas or works of art or gadgets or synthetic beings. The novel cautions us that human creativity begets things of great power, and dramatizes what happens when a creator significantly shirks his responsibility.

We’re still grappling with these same issues of creativity and responsibility—even if our scientific knowledge and technological sophistication are far more advanced today than in Shelley’s early 19th century. In an age of obviously Frankensteinian breakthroughs in genetic engineering, artificial intelligence, and social robotics, we’ve already answered the simpler question—we’re being hubristic, in some sense, playing with the forces of life and death. What remains is the deeper lesson at the heart of Frankenstein: That the thrill of discovery is just the beginning of a creator’s work.

Resource type: article: Web Page